Format

Send to

Choose Destination
Invest New Drugs. 2015 Oct;33(5):1108-14. doi: 10.1007/s10637-015-0269-8. Epub 2015 Jul 1.

Phase II study of tivantinib (ARQ 197) in patients with metastatic triple-negative breast cancer.

Author information

1
Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Yawkey 1257, Boston, MA, 02215, USA. stolaney@partners.org.
2
Harvard Medical School, Boston, MA, USA.
3
Department of Biostatistics and Computation Biology, Dana-Farber Cancer Institute, Boston, MA, USA.
4
Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
5
Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Yawkey 1257, Boston, MA, 02215, USA.
6
Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA.
7
Belfer Institute for Applied Cancer Sciences, Dana-Farber Cancer Institute, Boston, MA, USA.
8
Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD, USA.

Abstract

BACKGROUND:

MET expression and activation appear to be important for initiation and progression of triple-negative breast cancer. Tivantinib (ARQ 197) is an orally administered agent that targets MET, although recent preclinical data suggests the agent may have mechanisms of action that are independent of MET signaling. We conducted a phase 2 study of tivantinib monotherapy in patients with metastatic triple-negative breast cancer.

METHODS:

Patients with metastatic triple-negative breast cancer who had received 1 to 3 prior lines of chemotherapy in the metastatic setting were enrolled into this two-stage, single arm phase 2 study. Treatment consisted of twice daily oral dosing of tivantinib (360 mg po bid) during a 21-day cycle. Patients underwent restaging scans at 6 weeks, and then every 9 weeks. Tumor biomarkers that might predict response to tivantinib were explored.

RESULTS:

22 patients were enrolled. The overall response rate was 5 % (95 % CI 0-25 %) and the 6-month progression-free survival (PFS) was 5 % (95 % CI 0-25 %), with one patient achieving a partial response (PR). Toxicity was minimal with only 5 grade ≥3 adverse events (one grade 3 anemia, one grade 3 fatigue, and 3 patients with grade 3/4 neutropenia).

CONCLUSION:

This study represents the first evaluation of tivantinib for the treatment of metastatic triple-negative breast cancer. These results suggest that single agent tivantinib is well tolerated, but did not meet prespecified statistical targets for efficacy.

TRIAL REGISTRATION:

ClinicalTrials.gov NCT01575522.

KEYWORDS:

ARQ 197; MET; Tivantinib; Triple-negative breast cancer

PMID:
26123926
PMCID:
PMC4608248
DOI:
10.1007/s10637-015-0269-8
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Springer Icon for PubMed Central
Loading ...
Support Center